Tyme Technologies to Present at BioNJ’s 10th Annual BioPartnering Conference on October 6, 2020
14 September 2020 - 10:00PM
Business Wire
Tyme Technologies, Inc. (NASDAQ:TYME), an emerging
biotechnology company developing cancer metabolism-based therapies
(CMBTs™), announced that its leadership team will present at the
BioNJ 10th Annual BioPartnering Conference on Tuesday, October 6,
2020. The Company will present its corporate overview for fiscal
year 2021 with a special focus on multiple growth opportunities
driven by advances in the science of cell metabolism, SM-88
(racemetyrosine) pivotal and late-stage trials in pancreatic
cancer, SM-88 HopES trial in ultra-rare metastatic sarcoma,
proof-of-concept RESPOnD trial evaluating TYME-19 in COVID-19, and
expanding clinical plans for its cancer-metabolism pipeline
candidate SM-88 in pancreatic, prostate, breast and hematological
cancers.
Co-sponsored by J.P. Morgan and Johnson & Johnson
Innovation, the conference brings together biopharmaceutical
companies, investors, and academic collaborators across the
Northeast to Mid-Atlantic states.
Event: BioNJ’s 10th Annual BioPartnering Conference
Place: The Palace at Somerset Park in Somerset, NJ
Presentation Time: October 6th, 2020, 1:30 – 3:00 PM
ET
The presentation will be accessible on the events page under the
Investor Relations section of Tyme Technologies’ website at
www.tymeinc.com. There is no webcast for this event.
About SM-88 SM-88 is an oral investigational modified
proprietary tyrosine derivative that is believed to interrupt the
metabolic processes of cancer cells by breaking down the cells’ key
defenses and leading to cell death through oxidative stress and
exposure to the body’s natural immune system. Clinical trial data
have shown that SM-88 has demonstrated encouraging tumor responses
across 15 different cancers, including pancreatic, lung, breast,
prostate and sarcoma cancers with minimal serious grade 3 or higher
adverse events. Learn more.
About TYME-18 TYME-18 is composed of a proprietary
surfactant delivery agent with a specific sulfonic acid component.
It is designed for intra-tumoral administration of difficult to
treat tumors and leverages the acidic tumor microenvironment and
signaling pathways to kill cancer cells. TYME-18 is distinct in
composition, but like SM-88, aims to leverage susceptibilities of a
cancer that are related to its altered metabolism. Initial
preclinical data for TYME-18 in animal tumor models demonstrate
rapid and complete tumor regression, with no reported local or
systemic toxicities. TYME-18 continues to be studied as a potential
therapy for difficult to treat tumors that may not be eligible for
surgical or other interventions. Learn more.
About TYME-19 TYME-19 is a potent, well characterized
synthetic antiviral bile acid that is being evaluated as a
potential oral therapy for COVID-19. In preclinical testing,
TYME-19 repeatedly prevented COVID-19 viral replication without
attributable cytotoxicity in treated cells. COVID-19 hijacks a
cell’s ability to make proteins and lipids and divert these
processes to make viral proteins and lipids in order to reproduce.
COVID-19 accomplishes this by inducing stress in the endoplasmic
reticulum (ER), where cells process proteins, which enables the
virus to remodel protein and lipid synthesis. In preclinical
testing, TYME-19 has been shown to counteract these effects,
preventing viral replication, by reducing ER stress. TYME-19 is
believed to physically degrade viruses by solubilizing the
protective lipid layer and other structural components, which
prevent a virus from binding to and infecting a cell.
About TYME-88-Panc Pivotal Trial The TYME-88-Panc pivotal
trial applies the latest advances in the field of cancer metabolism
by evaluating the efficacy and safety of an oral investigational
compound that targets the metabolic mechanisms of the disease at
its source. A prospective, open label pivotal trial in metastatic
pancreatic cancer for patients who have failed two lines of any
prior systemic therapy. The trial is designed to evaluate the
safety and efficacy of SM-88 used with MPS (methoxsalen, phenytoin
and sirolimus) in advanced pancreatic cancer and will measure
multiple endpoints, including overall survival, progression free
survival, relevant biomarkers, quality of life, safety, and overall
response rate. Learn more.
About Tyme Technologies Tyme Technologies, Inc., is an
emerging biotechnology company developing cancer therapeutics that
are intended to be broadly effective across tumor types and have
low toxicity profiles. Unlike targeted therapies that attempt to
regulate specific mutations within cancer, the Company’s
therapeutic approach is designed to take advantage of a cancer
cell’s innate metabolic weaknesses to compromise its defenses,
leading to cell death through oxidative stress and exposure to the
body’s natural immune system. For more information, visit
www.tymeinc.com. Follow us on social media: @tyme_Inc, LinkedIn,
Instagram, Facebook and YouTube.
Forward-Looking Statements/Disclosure Notice In addition
to historical information, this press release contains
forward-looking statements under the Private Securities Litigation
Reform Act that involve substantial risks and uncertainties. The
forward-looking statements contained in this press release are
based on management's current expectations, which are subject to
uncertainty, risks and changes in circumstances that are difficult
to predict and many of which are outside of TYME's control. Factors
that could cause actual results to differ materially from these
forward-looking statements include the Company’s ability to
successfully implement its clinical and other plans, competitive
and regulatory developments, and the factors described in the
section captioned “Risk Factors” of TYME’s Annual Report on Form
10-K filed with the U.S. Securities and Exchange Commission (“SEC”)
on May 22, 2020, as well as subsequent reports and filings from
time to time with the SEC.
The information contained in this press release is as of release
date and TYME assumes no obligation to update forward-looking
statements contained in this release as a result of future events
or developments.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200914005106/en/
For Investor Relations & Media Inquiries: Investor Relations
1-212-461-2315 investorrelations@tymeinc.com media@tymeinc.com
Tyme Technologies (NASDAQ:TYME)
Historical Stock Chart
From Apr 2024 to May 2024
Tyme Technologies (NASDAQ:TYME)
Historical Stock Chart
From May 2023 to May 2024